BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study

Reuters12-17

Dec 17 (Reuters) - Biomea Fusion Inc BMEA.O:

BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM ONGOING PHASE II COVALENT-111 STUDY IN PATIENTS WITH TYPE 2 DIABETES
BIOMEA FUSION INC - ICOVAMENIB MEETS PRIMARY ENDPOINT WITH SIGNIFICANT REDUCTION IN HBA1C
BIOMEA FUSION INC - ICOVAMENIB WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

Source text: ID:nGNX5XcnRR

Further company coverage: BMEA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492696889?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-17 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492696889","market":"us","top_or_hot":-1,"title":"BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Biomea Fusion Inc <span>BMEA.O</span>:</p><ul><li><p>BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM ONGOING PHASE II COVALENT-111 STUDY IN PATIENTS WITH TYPE 2 DIABETES</p></li><li><p>BIOMEA FUSION INC - ICOVAMENIB MEETS PRIMARY ENDPOINT WITH SIGNIFICANT REDUCTION IN HBA1C</p></li><li><p>BIOMEA FUSION INC - ICOVAMENIB WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li></ul><p>Source text: <span>ID:nGNX5XcnRR</span></p><p>Further company coverage: <span>BMEA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 22:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 StudyDec 17 (Reuters) - Biomea Fusion Inc BMEA.O:BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM ONGOING...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:1","article_id":"2492696889","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492696889","pubTimestamp":1734444762,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 StudyDec 17 (Reuters) - Biomea Fusion Inc BMEA.O:BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM ONGOING","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BMEA":"Biomea Fusion, Inc.","BK4539":"次新股","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Biomea Fusion宣布正在进行的II期COVALENT-111研究的积极顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":0.9},"content_text":"BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 StudyDec 17 (Reuters) - Biomea Fusion Inc BMEA.O:BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM ONGOING PHASE II COVALENT-111 STUDY IN PATIENTS WITH TYPE 2 DIABETESBIOMEA FUSION INC - ICOVAMENIB MEETS PRIMARY ENDPOINT WITH SIGNIFICANT REDUCTION IN HBA1CBIOMEA FUSION INC - ICOVAMENIB WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTSSource text: ID:nGNX5XcnRRFurther company coverage: BMEA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492696889"}